At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 435 enrolled
Drug / intervention
Avacopan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Avacopan and Placebo for Hidradenitis Suppurativa and Acne Inversa. Completed, enrolled 435 participants across 91 sites.
Detailed Summary
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa, Acne Inversa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedFeb 2019
Primary CompletionJan 2021
Study CompletionMar 2021
TodayJul 2026
First PostedFeb 25, 2019
Enrollment StartDec 21, 2018
Primary CompletionJan 14, 2021
Study CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.4 years ago
Interventions
Avacopandrug
Active treatment
Placeboother
Placebo